The tissue transglutaminase IgG antibody test, or TTG-IgG for short, is a crucial diagnostic technique that is mostly used to identify celiac disease in people with low IgA levels. Immunoglobulin A (IgA) deficiency is a disorder in which the body fails to make enough IgA antibodies, rendering the more widely used TTG-IgA test useless. The tissue transglutaminase (TTG-IgG) test quantifies IgG antibodies, which are generally higher in celiac disease patients who do not have enough IgA.

The TTG-IgG test is primarily used to diagnose celiac disease, but because untreated celiac disease may have cardiovascular consequences, its implications also extend to the field of health heart diagnostics (HHD). Systemic inflammation and the inability to absorb vital nutrients are two consequences of celiac disease that might have an indirect impact on the cardiovascular